Oklahoma Blood Institute Sylvan N Goldman Center

CLIA Laboratory Citation Details

1
Total Citation
10
Total Deficiencyies
5
Unique D-Tags
CMS Certification Number 37D0470358
Address 1001 N Lincoln Boulevard, Oklahoma City, OK, 73104
City Oklahoma City
State OK
Zip Code73104
Phone(877) 340-8777

Citation History (1 survey)

Survey - February 26, 2018

Survey Type: Complaint

Survey Event ID: 1TP411

Deficiency Tags: D2000 D2013 D6076 D6089 D6089 D0000 D0000 D2000 D2013 D6076

Summary:

Summary Statement of Deficiencies D0000 A complaint survey was performed (State Complaint OK 00051556). The findings were reviewed with the vice-president of bio-development & QM, and the compliance officer at the conclusion of the survey. The laboratory was found out of compliance with following CLIA regulations: 1. 493.801; D2000: Enrollment and Testing of Samples 2. 493.1441; D6076: Laboratory Director D2000 ENROLLMENT AND TESTING OF SAMPLES CFR(s): 493.801 Each laboratory must enroll in a proficiency testing (PT) program that meets the criteria in subpart I of this part and is approved by HHS. The laboratory must enroll in an approved program or programs for each of the specialties and subspecialties for which it seeks certification. The laboratory must test the samples in the same manner as patients' specimens. For laboratories subject to 42 CFR part 493 published on March 14, 1990 (55 FR 9538) prior to September 1, 1992, the rules of this subpart are effective on September 1, 1992. For all other laboratories, the rules of this subpart are effective January 1, 1994. This CONDITION is not met as evidenced by: Based on a review of records, policies and procedures, and interview with the vice- president of bio-development & QM, compliance officer, OBI special project manager reference laboratory, and the OBI quality assessment director, the headquarters laboratory failed to enroll in proficiency testing for each sub-center laboratory certificate during 2015 and 2016. Findings include: The OBI headquarters laboratory engaged in proficiency testing referral during 2015 and 2016. Refer to D2013. D2013 TESTING OF PROFICIENCY TESTING SAMPLES CFR(s): 493.801(b)(4) The laboratory must not send proficiency testing samples or portions of proficiency Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 4 -- testing samples to another laboratory for any analysis for which it is certified to perform in its own laboratory. Any laboratory that CMS determines intentionally referred a proficiency testing sample to another laboratory for analysis may have its certification revoked for at least one year. If CMS determines that a proficiency testing sample was referred to another laboratory for analysis, but the requested testing was limited to reflex, distributive, or confirmatory testing that, if the sample were a patient specimen, would have been in full conformance with written, legally accurate and adequate standard operating procedures for the laboratory's testing of patient specimens, and if the proficiency testing referral is not a repeat proficiency testing referral, CMS will consider the referral to be improper and subject to alternative sanctions in accordance with 493.1804(c), but not intentional. Any laboratory that receives a proficiency testing sample from another laboratory for testing must notify CMS of the receipt of that sample regardless of whether the referral was made for reflex or confirmatory testing, or any other reason. This STANDARD is not met as evidenced by: Based on a review of records, policies and procedures, and interview with the vice- president of bio-development & QM, compliance officer, OBI special project manager reference laboratory, and the OBI quality assessment director, the OBI headquarters laboratory engaged in proficiency testing referral during 2015 and 2016. Findings include: (1) At the beginning of the survey, the surveyors interviewed the vice- president of bio-development & QM and the compliance officer (09:30 am) and asked them to explain the testing performed and the locations of the OBI (Oklahoma Blood Institute) centers. The vice-president of bio-development & QM and the compliance officer stated to the surveyors ABO Group typing, Rh (D) typing, Unexpected Antibody Detection, Antibody Identification, and Compatibility testing were performed at each of the following locations: (a) OBI headquarters (37D0470358) located in Oklahoma City, OK (b) Tulsa sub-center (37D0931105) located in Tulsa, OK (c) Ft. Smith sub-center (04D0469265) located in Ft. Smith, AR (d) Little Rock sub-center (04D2096885) located in Little Rock, AR (became operational November 2015) (2) The surveyors requested the proficiency testing (PT) policies for 2015 through 2018 from the compliance officer (11:10 am). The policy, titled "Proficiency Testing Program" (DOC: OBI-QM-SOP-0612) had been revised/reviewed since the 12 /22/14 policy as follows: (a) Revision 9 - Effective 12/22/14 (b) Revision 10 - Effective 06/01/15 (c) Revision 11 - Effective 04/11/16 (d) Revision 12 - Effective 12 /12/16 (this is when the new policy was in effect stating that each CLIA number must enroll in PT separately) (e) Revision 13 - Effective 10/02/17 (f) Revision 14 - Effective 01/15/18 (current policy) (3) The surveyors asked the OBI special project manager reference laboratory (11:40 am) to explain the process of ordering and performing PT during 2015, 2016, 2017, and to date in 2018. The OBI special project manager reference laboratory stated the following to the surveyors: (a) During 2015 - Transfusion Medicine PT events J-A, J-B, and J-C ordered through CAP (College of American Pathologists) under the OBI headquarters CLIA number (37D0470358): (i) Each shipment from CAP (containing 3 test kits) was shipped to the headquarters location (each test kit consisted of a sealed styrofoam package which contained PT samples, and PT paperwork such as report forms, attestation forms, etc.). The OBI headquarters then distributed the unopened styrofoam test kits as follows: (aa) Kit #1 - Remained at the OBI headquarters (bb) Kit #2 - Delivered to the Tulsa sub-center by OBI courier (cc) Kit #3 - Delivered to the Ft. Smith sub-center by OBI courier (ii) The samples from each test kit were tested at each location, with result forms and attestations completed at each site. The completed paperwork (hard copies) were delivered by OBI courier back to the OBI headquarters in a red folder from each -- 2 of 4 -- location; (iii) The OBI special project manager reference laboratory electronically entered all PT results for each of the test kits as they were received in the Oklahoma City office from each sub-center. After the final set of results were received from a sub-center, the results were electronically submitted to CAP; (iv) All hardcopies contained in the red folders for the headquarters and each sub-center location were maintained on-site at the OBI headquarters location; (v) Graded evaluations were emailed to the OBI special project manager reference laboratory from CAP; (vi)

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access